Sector Expert: David Luci
David Luci is cofounder of Dipexium Pharmaceuticals Inc., and currently serves as president, CEO, secretary and director. From January 2010 to March 2014, he served as managing partner of the company. From 2007 to January 2010, Mr. Luci served as a member of the board of directors of Access Pharmaceuticals Inc., where he also served as chairman of the Audit Committee and the Compensation Committee, and served in a consulting capacity following the acquisition of MacroChem Corp. From December 2007 through February 2009, he served as a member of the board of directors and in several management capacities at MacroChem, including president, CFO and general counsel. Prior to that, Mr. Luci served as executive vice president, CFO, general counsel and corporate secretary of Bioenvision Inc., an international biopharmaceutical company engaged in the development, marketing and commercialization of oncology products. He was instrumental in creating Bioenvision's international commercial enterprise; managed the worldwide development of Evoltra (clofarabine) as a member of the product's joint steering committee partner, Genzyme Corp.; and orchestrated, structured and negotiated the sale of Bioenvision in 2007 to Genzyme for $345M. Mr. Luci began his career with Ernst & Whinney LLP (now Ernst & Young LLP) as a certified public accountant working in the Healthcare Practice Group. He later practiced corporate law at Paul Hastings LLP in New York, where his practice encompassed all aspects of public and private mergers and acquisitions, corporate finance, restructurings and private equity transactions, with a core focus in the healthcare industry. He graduated from Bucknell University with a bachelor of science degree in business administration (accounting), and graduated from Albany Law School of Union University. Mr. Luci became a certified public accountant in Pennsylvania in 1990 (inactive) and is a member of the New York State Bar Association.
Dipexium Pairs the African Clawed Frog and Business Savvy for an Antibiotic Wound Care Solution (5/7/15)
David Luci, CEO of Dipexium Pharmaceuticals Inc., tells The Life Sciences Report why he believes his firm's new skin-healing product may soon dominate a broad international market niche. Investors take note: Not only is the company's product promising, its top management also spearheaded a successful initial public offering—a combo that could prove a potent addition to a biotech portfolio.